Flag of the European Union EU Clinical Trials Register Help

Clinical trials for roxall

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44379   clinical trials with a EudraCT protocol, of which   7391   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    12 result(s) found for: roxall. Displaying page 1 of 1.
    EudraCT Number: 2011-002317-10 Sponsor Protocol Number: SC-31A Start Date*: 2019-04-17
    Sponsor Name:ROXALL Medizin GmbH
    Full Title: Phase II study to assess the tolerability, safety and efficacy of subcutaneous cluster-immunotherapy in patients suffering from house dust mite allergy
    Medical condition: Allergic rhinitis / rhino-conjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    20.0 100000004870 10020419 House dust mite allergy LLT
    21.1 100000004855 10034382 Perennial allergic rhinitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022083-12 Sponsor Protocol Number: SC-11A Start Date*: 2014-05-15
    Sponsor Name:ROXALL Medizin GmbH
    Full Title: Evaluation of tolerability and efficacy of subcutaneous cluster-immunotherapy in patients with allergic rhinitis / rhino-conjunctivitis due to grass pollen
    Medical condition: Allergic rhinitis / rhino-conjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004870 10001726 Allergic rhinitis due to pollen LLT
    19.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-002301-29 Sponsor Protocol Number: SL-51A Start Date*: Information not available in EudraCT
    Sponsor Name:ROXALL Medicina España S.A.
    Full Title: PHASE II STUDY TO ASSESS THE TOLERABILITY, SAFETY AND EFFICACY OF SUBLINGUAL IMMUNOTHERAPY IN PATIENTS SUFFERING FROM GRASS POLLEN ALLERGY
    Medical condition: Patients with grass pollen related allergic rhinitis/rhino-conjunctivitis (with or without well controlled asthma).
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-002321-22 Sponsor Protocol Number: SL-71A Start Date*: 2020-08-06
    Sponsor Name:Roxall Medicina España S.A.
    Full Title: PHASE II STUDY TO ASSESS THE TOLERABILITY, SAFETY AND EFFICACY OF SUBLINGUAL IMMUNOTHERAPY IN PATIENTS SUFFERING FROM HOUSE DUST MITE ALLERGY
    Medical condition: Patients with house dust mites related allergic rhinitis/rhino-conjunctivitis (with or without well controlled asthma).
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-006533-19 Sponsor Protocol Number: SC-312A Start Date*: 2022-11-15
    Sponsor Name:ROXALL Medizin GmbH
    Full Title: Phase II-III study to assess the efficacy and safety of subcutaneous cluster-immunotherapy in patients suffering from grass pollen allergy
    Medical condition: Patients with grass pollen-related allergic rhinitis/rhinoconjunctivitis and well-controlled mild-to-moderate or without asthma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10039085 Rhinitis allergic PT
    20.0 10015919 - Eye disorders 10010744 Conjunctivitis allergic PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-000513-29 Sponsor Protocol Number: CLU-2008-001 Start Date*: 2008-09-30
    Sponsor Name:ROXALL Medizin GmbH
    Full Title: Efficacy and safety of subcutaneous cluster immunotherapy with cluster-allergoid CLUSTOID® (glutaraldehyde-polymerized allergen extract of mixtures of grass and rye allergens – Holcus lanatus, Dact...
    Medical condition: This clinical trial will evaluate the benefit of subcutaneous cluster immunotherapy with cluster-allergoid CLUSTOID® over placebo in patients with allergic rhinoconjunctivits.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-002296-42 Sponsor Protocol Number: SC-21A Start Date*: 2020-01-31
    Sponsor Name:ROXALL Medizin GmbH
    Full Title: Phase II study to assess the tolerability, safety and efficacy of subcutaneous cluster-immunotherapy in patients suffering from birch pollen allergy
    Medical condition: Allergic rhinitis / rhino-conjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10001723 Allergic rhinitis LLT
    20.0 100000004870 10001726 Allergic rhinitis due to pollen LLT
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    20.1 100000004870 10066093 Birch pollen allergy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002319-27 Sponsor Protocol Number: SL-61A Start Date*: 2021-02-01
    Sponsor Name:ROXALL Medizin GmbH
    Full Title: Phase II study to assess the tolerability, safety and efficacy of sublingual immunotherapy in patients suffering from birch pollen allergy
    Medical condition: Birch pollen-related allergic rhinitis / rhino-conjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10001723 Allergic rhinitis LLT
    20.0 100000004870 10001726 Allergic rhinitis due to pollen LLT
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    20.1 100000004870 10066093 Birch pollen allergy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-001610-19 Sponsor Protocol Number: SC-332A Start Date*: 2023-02-27
    Sponsor Name:ROXALL Medizin GmbH
    Full Title: Phase II-III study to assess the efficacy and safety of subcutaneous cluster-immunotherapy in patients suffering from house dust mite allergy
    Medical condition: Patients with house dust mite-related allergic rhinitis/rhino-conjunctivitis and with well-controlled mild-to-moderate or without asthma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10039085 Rhinitis allergic PT
    20.0 10015919 - Eye disorders 10010744 Conjunctivitis allergic PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002881-42 Sponsor Protocol Number: SL-351A Start Date*: 2023-02-07
    Sponsor Name:ROXALL Medizin GmbH
    Full Title: Phase II study to assess the tolerability, safety and efficacy of sublingual immunotherapy in patients suffering from grass pollen allergy
    Medical condition: Patients with grass pollen-related allergic rhinitis/rhino-conjunctivitis (with well-controlled mild-to-moderate or without asthma)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10001723 Allergic rhinitis LLT
    20.0 100000004870 10001726 Allergic rhinitis due to pollen LLT
    20.0 100000004853 10001709 Allergic conjunctivitis LLT
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-005169-41 Sponsor Protocol Number: SL-372A Start Date*: 2023-03-16
    Sponsor Name:ROXALL Medizin GmbH
    Full Title: Phase II-III study to assess efficacy and safety of sublingual immunotherapy in patients suffering from house dust mite allergy
    Medical condition: Patients with house dust mites related allergic rhinitis/rhinoconjunctivitis and well-controlled mild-to-moderate or without asthma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10039085 Rhinitis allergic PT
    20.0 10015919 - Eye disorders 10010744 Conjunctivitis allergic PT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-001587-97 Sponsor Protocol Number: SC-322A Start Date*: 2023-04-06
    Sponsor Name:ROXALL Medizin GmbH
    Full Title: Phase II-III study to assess the efficacy and safety of subcutaneous cluster-immunotherapy in patients suffering from birch pollen allergy
    Medical condition: Patients with birch pollen-related allergic rhinitis/rhinoconjunctivitis and with well-controlled mild-to-moderate or without asthma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10039085 Rhinitis allergic PT
    20.0 10015919 - Eye disorders 10010744 Conjunctivitis allergic PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Feb 09 02:28:06 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA